Outcomes of secondary primary malignancies among patients with diffuse large B-cell lymphoma.
1/5 보강
[BACKGROUND] An increased risk of secondary primary malignancies (SPMs) has been shown in diffuse large B-cell lymphoma (DLBCL) patients after treatment.
- p-value P < 0.001
- p-value P = 0.032
APA
Xu P, Lin Y, et al. (2025). Outcomes of secondary primary malignancies among patients with diffuse large B-cell lymphoma.. Discover oncology, 16(1), 1034. https://doi.org/10.1007/s12672-025-02897-2
MLA
Xu P, et al.. "Outcomes of secondary primary malignancies among patients with diffuse large B-cell lymphoma.." Discover oncology, vol. 16, no. 1, 2025, pp. 1034.
PMID
40488928 ↗
Abstract 한글 요약
[BACKGROUND] An increased risk of secondary primary malignancies (SPMs) has been shown in diffuse large B-cell lymphoma (DLBCL) patients after treatment. However, research on SPM outcomes in DLBCL patients is limited.
[METHODS] Utilizing the population-based Surveillance, Epidemiology, and End Results Registry (SEER), the authors examined the characteristics, overall survival (OS), and treatments in DLBCL patients who developed secondary cancers of the breast, prostate, lung, colon/rectum, bladder cancers, melanoma, myeloma, and acute leukemia. Each patient was matched by age, sex, race, year of diagnosis, and stage to 50 controls from a general population diagnosed with a non-DLBCL primary the cancer.
[RESULTS] Patients with antecedent DLBCL who developed lung cancer (37.3% vs. 18.3%, P < 0.001) or colon/rectum cancer (45.5% vs. 39.6%, P = 0.032) were more commonly diagnosed at an early stage. Compared with patients in the control group, patients with antecedent DLBCL who developed prostate cancer, melanoma, myeloma, and acute leukemia had significantly worse OS. Conversely, patients who developed lung cancer after their antecedent DLBCL diagnosis showed markedly better OS. Amongst patients with antecedent DLBCL aged over 60, intensive therapy was associated with improved OS compared to supportive care in those being treated for a SPM diagnosis of breast, prostate, lung, colon/rectum, melanoma or bladder cancer, but not myeloma or acute leukemia. The rates of surgical resection were the same between patients with antecedent DLBCL and those in the control group, except for lower prostatectomy rates and higher lobectomy rates among patients with antecedent DLBCL.
[CONCLUSIONS] Our findings can assist clinicians in better understanding the survival outcomes of SPMs among patients with antecedent DLBCL while suggesting that long-term follow-up might be useful to detect DLBCL survivors who developed SPMs.
[METHODS] Utilizing the population-based Surveillance, Epidemiology, and End Results Registry (SEER), the authors examined the characteristics, overall survival (OS), and treatments in DLBCL patients who developed secondary cancers of the breast, prostate, lung, colon/rectum, bladder cancers, melanoma, myeloma, and acute leukemia. Each patient was matched by age, sex, race, year of diagnosis, and stage to 50 controls from a general population diagnosed with a non-DLBCL primary the cancer.
[RESULTS] Patients with antecedent DLBCL who developed lung cancer (37.3% vs. 18.3%, P < 0.001) or colon/rectum cancer (45.5% vs. 39.6%, P = 0.032) were more commonly diagnosed at an early stage. Compared with patients in the control group, patients with antecedent DLBCL who developed prostate cancer, melanoma, myeloma, and acute leukemia had significantly worse OS. Conversely, patients who developed lung cancer after their antecedent DLBCL diagnosis showed markedly better OS. Amongst patients with antecedent DLBCL aged over 60, intensive therapy was associated with improved OS compared to supportive care in those being treated for a SPM diagnosis of breast, prostate, lung, colon/rectum, melanoma or bladder cancer, but not myeloma or acute leukemia. The rates of surgical resection were the same between patients with antecedent DLBCL and those in the control group, except for lower prostatectomy rates and higher lobectomy rates among patients with antecedent DLBCL.
[CONCLUSIONS] Our findings can assist clinicians in better understanding the survival outcomes of SPMs among patients with antecedent DLBCL while suggesting that long-term follow-up might be useful to detect DLBCL survivors who developed SPMs.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Digital Health Management via IKAP Theory Improves Upper Limb Function and Psychological Adaptation in Postmastectomy Patients: A Randomized Controlled Trial.
- Chaperonin in health and disease.
- Exploring the characteristics of gut microbiome changes in lung cancer patients and healthy controls.
- Leptomeningeal metastasis from large-cell neuroendocrine carcinoma of the cervix: a case report and literature review.
- Multiplex CD30/Carbonic Anhydrase IX Lateral Flow Assay for Rapid Triage of Suspected BIA-ALCL in Peri-implant Seroma Fluid.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A novel real-world data methodology for lymphoma outcome classification: the real-world Lugano study.
- Case Report: Secondary neurolymphomatosis successfully treated with sequential Bruton's tyrosine kinase inhibitor and bispecific antibody therapy.
- Correction: Survival disparities and predictors in gastric cancer: a population-based study from Kazakhstan (2012-2023).
- Breast Implant-Associated Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma.
- Patterns and prognostic implications of cutaneous metastasis in Hong Kong: A multicenter analysis.
- Integrative Molecular Insights Into Epidemiological, Genetic, and Metabolic Risk Factors of Gallbladder Cancer: Implications for Biomarkers, Therapeutic Targeting, and Future Perspectives.